We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.

placeholder="Enter search term...">
Suitcase

ACWY Vax (meningococcal polysaccharide groups A, C, W135 and Y vaccine) Safety Information

22 May 2014

GlaxoSmithkline (GSK) has posted a letter to healthcare professionals on new data relating to ACWY Vax (meningococcal polysaccharide groups A, C, W135 and Y vaccine):

The current product information for ACWY Vax states an antibody persistence of at least 3 years. New data, however, demonstrate a waning of antibody titres between one and two years after ACWY Vax vaccination.

  • Individuals who remain at high risk of exposure to Neisseria meningitidis should be considered for revaccination earlier than currently recommended.
  • Conjugate vaccines are recommended when revaccination within 2 years after administration of the previous ACWY Vax dose is considered.

Healthcare professionals are advised to use their own judgement as to what they do with this information and how actively they cascade this new information to travellers previously vaccinated with ACWY Vax.

Healthcare professionals should use their clinical judgement following individual risk assessment when deciding whether to revaccinate travellers considered to be at particular risk.